keyword
MENU ▼
Read by QxMD icon Read
search

Acute myeloid leukaemia

keyword
https://www.readbyqxmd.com/read/29767839/jak2-v617f-positive-acute-myeloid-leukaemia-aml-a-comparison-between-de-novo-aml-and-secondary-aml-transformed-from-an-underlying-myeloproliferative-neoplasm-a-study-from-the-bone-marrow-pathology-group
#1
Jason Aynardi, Rashmi Manur, Paul R Hess, Seble Chekol, Jennifer J D Morrissette, Daria Babushok, Elizabeth Hexner, Heesun J Rogers, Eric D Hsi, Elizabeth Margolskee, Attilio Orazi, Robert Hasserjian, Adam Bagg
The JAK2 V617F mutation is characteristic of most Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) and occurs rarely in de novo acute myeloid leukaemia (AML). We sought to characterize AMLs that harbour this mutation and distinguish those that arise de novo (AML-DN) from those that reflect transformation of an underlying MPN (AML-MPN). Forty-five patients with JAK2 V617F-mutated AML were identified; 15 were AML-DN and 30 were AML-MPN. AML-MPN cases were more likely to have splenomegaly (P = 0·02), MPN-like megakaryocytes and higher mean JAK2 V617F VAF at diagnosis (P = 0·04)...
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29767474/mesenchymal-stromal-cells-from-shwachman-diamond-syndrome-patients-fail-to-recreate-a-bone-marrow-niche-in-vivo-and-exhibit-impaired-angiogenesis
#2
Donatella Bardelli, Erica Dander, Cristina Bugarin, Claudia Cappuzzello, Alice Pievani, Grazia Fazio, Paolo Pierani, Paola Corti, Piero Farruggia, Carlo Dufour, Simone Cesaro, Marco Cipolli, Andrea Biondi, Giovanna D'Amico
Shwachman-Diamond syndrome (SDS) is a rare multi-organ recessive disease mainly characterised by pancreatic insufficiency, skeletal defects, short stature and bone marrow failure (BMF). As in many other BMF syndromes, SDS patients are predisposed to develop a number of haematopoietic malignancies, particularly myelodysplastic syndrome and acute myeloid leukaemia. However, the mechanism of cancer predisposition in SDS patients is only partially understood. In light of the emerging role of mesenchymal stromal cells (MSCs) in the regulation of bone marrow homeostasis, we assessed the ability of MSCs derived from SDS patients (SDS-MSCs) to recreate a functional bone marrow niche, taking advantage of a murine heterotopic MSC transplant model...
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29767433/t-6-9-p23-q34-1-acute-myeloid-leukaemia-with-cup-like-blasts
#3
Claire Bories, Thomas Boyer
No abstract text is available yet for this article.
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29767427/azacitidine-in-the-real-world-an-evaluation-of-1101-higher-risk-myelodysplastic-syndrome-low-blast-count-acute-myeloid-leukaemia-patients-in-ontario-canada
#4
Lee Mozessohn, Matthew C Cheung, Saber Fallahpour, Tripat Gill, Asmaa Maloul, Liying Zhang, Olivia Lau, Rena Buckstein
The outcome of myelodysplastic syndrome (MDS) patients with uniformly higher-risk disease treated with azacitidine (AZA) in the 'real-world' remains largely unknown. We evaluated 1101 consecutive higher-risk MDS patients (International Prognostic Scoring System intermediate-2/high) and low-blast count acute myeloid leukaemia (AML; 21-30% blasts) patients treated in Ontario, Canada. By dosing schedule, 24·7% received AZA for seven consecutive days, 12·4% for six consecutive days and 62·9% by 5-2-2. Overall, median number of cycles was 6 (range 1-67) and 8 (range 6-14) when restricted to the 692 (63%) patients who received at least 4 cycles...
May 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29765150/phase-i-studies-of-azd1208-a-proviral-integration-moloney-virus-kinase-inhibitor-in-solid-and-haematological-cancers
#5
Jorge Cortes, Kenji Tamura, Daniel J DeAngelo, Johann de Bono, David Lorente, Mark Minden, Geoffrey L Uy, Hagop Kantarjian, Lisa S Chen, Varsha Gandhi, Robert Godin, Karen Keating, Kristen McEachern, Karthick Vishwanathan, Janet Elizabeth Pease, Emma Dean
BACKGROUND: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tumours. METHODS: Two dose-escalation studies were performed to evaluate the safety and tolerability, and to define the maximum tolerated dose (MTD), of AZD1208 in AML and solid tumours...
May 16, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29761849/muc1-c-drives-myeloid-leukaemogenesis-and-resistance-to-treatment-by-a-survivin-mediated-mechanism
#6
Dina Stroopinsky, Hasan Rajabi, Myrna Nahas, Jacalyn Rosenblatt, Maryam Rahimian, Athalia Pyzer, Ashujit Tagde, Akriti Kharbanda, Salvia Jain, Turner Kufe, Rebecca K Leaf, Eleni Anastasiadou, Michal Bar-Natan, Shira Orr, Maxwell D Coll, Kristen Palmer, Adam Ephraim, Leandra Cole, Abigail Washington, Donald Kufe, David Avigan
Acute myeloid leukaemia (AML) is an aggressive haematological malignancy with an unmet need for improved therapies. Responses to standard cytotoxic therapy in AML are often transient because of the emergence of chemotherapy-resistant disease. The MUC1-C oncoprotein governs critical pathways of tumorigenesis, including self-renewal and survival, and is aberrantly expressed in AML blasts and leukaemia stem cells (LSCs). However, a role for MUC1-C in linking leukaemogenesis and resistance to treatment has not been described...
May 15, 2018: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/29755703/gut-colonization-with-carbapenem-resistant-enterobacteriaceae-adversely-impacts-the-outcome-in-patients-with-hematological-malignancies-results-of-a-prospective-surveillance-study
#7
Sarita Rani Jaiswal, Satyanker Gupta, Rekha Saji Kumar, Amit Sherawat, Ashok Rajoreya, Saroj K Dash, Gitali Bhagwati, Suparno Chakrabarti
Background: Gut colonisation with carbapenem-resistant enterobacteriaceae (CRE) is a risk factor for CRE bacteremia and patients with haematological malignancies (HM) are at the highest risk of mortality. Methods: We conducted a prospective surveillance study of gut colonisation with CRE and its impact on the outcome of 225 consecutive patients of HM over 28 months. Results: The median age of the cohort was 46 years, the majority with acute leukaemia...
2018: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/29747272/-analysis-of-proliferative-lesions-of-haematopoietic-and-lymphoid-tissue-in-the-female-productive-tract
#8
D B Chen, H Zhang, Y H Zhang, Y Wang, Q J Song, S M Yang, H Cui, Y Zhao, X Z Fang, D H Shen
Objective: To study the clinicopathologic features, diagnosis and differential diagnosis of tumors of haematopoietic and lymphoid tissue in the female productive tract. Methods: Eleven cases of myeloid sarcoma and leukemia, 9 of non Hodgkin lymphoma (NHL) , 13 of cervical lymphoma-like lesions were selected from Peking University People's Hospital from January 2006 to August 2017. According to WHO classification of tumors of haematopoietic and lymphoid tissues (2008) and updated classification(2016), the cases were studied by microscopy, immunohistochemistry and in situ hybridization...
April 25, 2018: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/29745850/feedback-regulation-in-a-stem-cell-model-with-acute-myeloid-leukaemia
#9
Jianfeng Jiao, Min Luo, Ruiqi Wang
BACKGROUND: The haematopoietic lineages with leukaemia lineages are considered in this paper. In particular, we mainly consider that haematopoietic lineages are tightly controlled by negative feedback inhibition of end-product. Actually, leukemia has been found 100 years ago. Up to now, the exact mechanism is still unknown, and many factors are thought to be associated with the pathogenesis of leukemia. Nevertheless, it is very necessary to continue the profound study of the pathogenesis of leukemia...
April 24, 2018: BMC Systems Biology
https://www.readbyqxmd.com/read/29741260/acute-myeloid-leukaemia-how-to-combine-multiple-tools
#10
A Merino, L Boldú, A Ermens
The pathogenesis of acute myeloid leukaemias (AML) frequently requires at least 3 mutations in different cellular pathways. In many cases, mutations in proliferation/survival mechanisms and differentiation pathways are involved. Genetic aberrations explain the pathogenesis of AML, provide prognostic criteria and guide drug design for future therapy. Since the last update of the World Health Organization (WHO) classification of tumours of the hematopoietic and lymphoid tissues in 2008, there have been many discovers regarding the genomic landscape of AML and molecular assays for the detection of minimal residual disease...
May 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29724869/cutaneous-herald-leukaemia-cutis-as-presenting-manifestation-of-relapse-in-acute-promyelocytic-leukaemia
#11
Prasanth Balasubramanian, Ram V Nampoothiri, Deepak Goni, Pankaj Malhotra
Leukaemia cutis or cutaneous infiltration of neoplastic myeloid or lymphoid cells is usually seen in the acute myelomonocytic and acute monocytic variants of acute myeloid leukaemia. Here, we report a case of acute promyelocytic leukaemia who achieved remission, presenting with skin lesions, the biopsy of which revealed leukaemia cutis, heralding the relapse of the disease. After establishing the diagnosis with bone marrow analysis, the patient was started on daunorubicin chemotherapy along with arsenic trioxide and all-trans retinoic acid...
May 2, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29719925/prognostic-markers-in-core-binding-factor-aml-and-improved-survival-with-multiple-consolidation-cycles-of-intermediate-high-dose-cytarabine
#12
Ashvind Prabahran, Mark Tacey, Shaun Fleming, Andrew Wei, Courtney Tate, Paula Marlton, Joel Wight, Andrew Grigg, Annabel Tuckfield, Jeff Szer, David Ritchie, Lynette Chee
OBJECTIVES: Core-binding factor acute myeloid leukaemia (CBF AML) defined by t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) has a favourable prognosis, however 30-40% of patients still relapse after chemotherapy. We sought to evaluate risk factors for relapse in a de novo CBF AML cohort. PATIENTS/MATERIALS/METHODS: A retrospective review of patients from 4 Australian tertiary centres from 2001-2012, comprising 40 t(8;21) and 30 inv(16) AMLs. RESULTS: Multivariate analysis identified age (p=0...
May 2, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29700093/from-genomics-to-targeted-treatment-in-haematological-malignancies-a-focus-on-acute-myeloid-leukaemia
#13
Niels Asger Jakobsen, Paresh Vyas
The haematological malignancies are a heterogeneous group of neoplastic disorders, which lead to almost 10,000 deaths annually in the UK. Over the past 2 decades, there has been significant progress in our understanding of the pathological mechanisms underlying these cancers, accompanied by improvements in outcomes for some patients. In particular, advances in next-generation sequencing now make it possible to define the genetic lesions present in each patient, which has led to improved disease classification, risk stratification and identification of new therapeutic targets...
April 1, 2018: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/29699481/computer-simulations-of-the-signalling-network-in-flt3-acute-myeloid-leukaemia-indications-for-an-optimal-dosage-of-inhibitors-against-flt3-and-cdk6
#14
Antoine Buetti-Dinh, Ran Friedman
BACKGROUND: Mutations in the FMS-like tyrosine kinase 3 (FLT3) are associated with uncontrolled cellular functions that contribute to the development of acute myeloid leukaemia (AML). We performed computer simulations of the FLT3-dependent signalling network in order to study the pathways that are involved in AML development and resistance to targeted therapies. RESULTS: Analysis of the simulations revealed the presence of alternative pathways through phosphoinositide 3 kinase (PI3K) and SH2-containing sequence proteins (SHC), that could overcome inhibition of FLT3...
April 24, 2018: BMC Bioinformatics
https://www.readbyqxmd.com/read/29692658/atypical-chronic-myeloid-leukaemia-a-rare-subtype-of-myelodysplastic-myeloproliferative-neoplasm
#15
REVIEW
Joanna E Drozd-Sokołowska, Anna Waszczuk-Gajda, Krzysztof Mądry, Jadwiga Dwilewicz-Trojaczek
Atypical chronic myeloid leukaemia (aCML) belongs to the group of myelodysplastic/myeloproliferative neoplasms. Changing diagnostic criteria and the rarity of the disease, with incidence approximately 100-times lower than the incidence of BCR-ABL1 -positive chronic myeloid leukaemia, result in limited knowledge on aCML. At present the diagnosis is made based on the presence of granulocytic lineage dysplasia and precisely defined quantitative peripheral blood criteria, after exclusion of other molecularly defined myeloid neoplasms...
2018: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/29687483/the-diagnosis-and-treatment-of-invasive-aspergillosis-in-dutch-haematology-units-facing-a-rapidly-increasing-prevalence-of-azole-resistance-a-nationwide-survey-and-rationale-for-the-db-msg-002-study-protocol
#16
Alexander F A D Schauwvlieghe, Nick de Jonge, Karin van Dijk, Paul E Verweij, Roger J Brüggemann, Bart J Biemond, Aldert Bart, Peter A von dem Borne, Annelies Verbon, Martha T van der Beek, Astrid M P Demandt, Guy J Oudhuis, Jan J Cornelissen, Walter J F M van der Velden, Lambert F R Span, Greetje A Kampinga, Anke H Bruns, Alieke G Vonk, Pieter-Jan A Haas, Jeanette K Doorduijn, Bart J A Rijnders
BACKGROUND: Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). A survey was conducted in all Dutch academic haematology centres on their current diagnostic, prophylactic and therapeutic approach towards IFD in the context of azole resistance. METHODS: In all 8 centres, a haematologist and microbiologist filled in the questionnaire that focused on different subgroups of haematology patients. RESULTS: Fungal prophylaxis during neutropenia was directed against Candida and consisted of fluconazole and/or amphotericin B suspension...
April 23, 2018: Mycoses
https://www.readbyqxmd.com/read/29683259/genital-ulcers-as-diagnostic-clue-for-acute-myeloid-leukaemia
#17
Sina D Schröder, Stefan W Krause, Cornelia Erfurt-Berge
Acute myeloid leukaemia is a myeloid neoplasm with an extremely varying clinical appearance. Skin lesions are common for specific subtypes of acute myeloid leukaemia but are often misinterpreted. Here, we present a case of acute myeloid leukaemia in a young woman exhibiting genital ulcerations and gingival erosions.
April 23, 2018: International Wound Journal
https://www.readbyqxmd.com/read/29676467/immunophenotypic-analysis-of-cell-cycle-status-in-acute-myeloid-leukaemia-relationship-to-cytogenetics-genotype-and-clinical-outcome
#18
Rob S Sellar, Rosemary E Gale, Asim Khwaja, Maciej Garbowski, Marco Loddo, Kai Stoeber, Gareth H Williams, David C Linch
Cell cycle status may play an important role in directing patient therapy. We therefore determined the cell cycle status of leukaemic cells by immunophenotypic analysis of bone marrow trephine biopsies from 181 patients with acute myeloid leukaemia (AML) and correlated the results with biological features and clinical outcome. There was considerable heterogeneity between patients. The presenting white cell count significantly correlated with the proportion of non-quiescent cells (P < 0·0001), of cycling cells beyond G1 (P < 0·0001) and the speed of cycling (P < 0·0001)...
April 20, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29663325/a-new-approach-to-the-treatment-of-acute-myeloid-leukaemia-targeting-the-receptor-for-growth-hormone-releasing-hormone
#19
Joaquin J Jimenez, Gina M DelCanto, Petra Popovics, Aymee Perez, Ailin Vila Granda, Irving Vidaurre, Ren-Zhi Cai, Ferenc G Rick, Ronan T Swords, Andrew V Schally
Growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and acts on the pituitary gland to stimulate the release of growth hormone (GH). GHRH can also be produced by human cancers, in which it functions as an autocrine/paracrine growth factor. We have previously shown that synthetic antagonistic analogues of GHRH are able to successfully suppress the growth of 60 different human cancer cell lines representing over 20 cancers. Nevertheless, the expression of GHRH and its receptors in leukaemias has never been examined...
April 16, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29643104/actigraphy-assessment-of-sleep-quality-among-patients-with-acute-myeloid-leukaemia-during-induction-chemotherapy
#20
Chi-Fu Jeffrey Yang, Kelli Aibel, Ryan Meyerhoff, Frances Wang, David Harpole, Amy P Abernethy, Thomas W LeBlanc
OBJECTIVES: Patients receiving induction chemotherapy for acute myeloid leukaemia (AML) anecdotally describe poor sleep, but sleep disturbances have not been well-characterised in this population. We aimed to test the feasibility of measuring sleep quality in AML inpatients using a wearable actigraphy device. METHODS: Using the Actigraph GT3X 'watch', we assessed the total sleep time, sleep onset latency, wake after sleep onset, number of awakenings after sleep onset and sleep efficiency for inpatients with AML receiving induction chemotherapy...
April 11, 2018: BMJ Supportive & Palliative Care
keyword
keyword
25318
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"